|Articles|January 1, 2002

January 2002
Volume 8
Issue 1

Issues in Pooling Administrative Data for Economic Evaluation

Author(s)Richard T. Meenan, PhD, MPH, Michael J. Goodman, PhD, Paul A. Fishman, PhD

Download PDF: Issues in Pooling Administrative Data for Economic Evaluation

Articles in this issue

over 24 years ago

Article

TennCare - Medicaid Managed Care in Tennessee in Jeopardy

over 24 years ago

Article

Effects of Restrictive Formularies in the Ambulatory Care Setting

over 24 years ago

Article

The Generalist's Patient and the Subspecialist

over 24 years ago

Article

Postmenopausal Hormone Replacement Therapy and Major Clinical Outcomes: A Focus on Cardiovascular Disease, Osteoporosis, Dementia, and Breast and Endometrial Neoplasia

over 24 years ago

Article

Can Guidelines Impact the Ordering of Magnetic Resonance Imaging Studies by Primary Care Providers for Low Back Pain?

over 24 years ago

Article

Accuracy of Computerized Outpatient Diagnoses in a Veterans Affairs General Medicine Clinic

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Issues in Pooling Administrative Data for Economic Evaluation

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO